1-9 of 9
Sebastian Schellong
Close
Sort by
Journal Articles

Venous Thromboembolism in Children, Adolescents and Young Adults: Findings from the Riete Registry

Omri Cohen, Assaf Arie Barg, Ulrike Nowak-Göttl, Reina Valle, Lucia Mazzolai, Gregorio Tiberio, Sebastian Schellong, Andris Skride, Mª del Valle Morales, Manuel Monreal, Gili Kenet
Journal: Blood
Blood (2022) 140 (Supplement 1): 5692–5693.
https://doi.org/10.1182/blood-2022-159499
Published: 2022
Journal Articles

Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosis - the Surprise Trial

Jan Beyer-Westendorf, MD, Sebastian Schellong, MD, Horst Gerlach, MD, Katja Jersemann, Eberhard Rabe, MD, Kurtulus Sahin, Rupert Bauersachs, MD PhD
Journal: Blood
Blood (2016) 128 (22): 85.
https://doi.org/10.1182/blood.V128.22.85.85
Published: 2016
Journal Articles

Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER ® and RE-COVER II™

Sebastian Schellong, MD, Henry Eriksson, MD PhD, Samuel Z. Goldhaber, MD, Martin Feuring, MD, Stefan Hantel, PhD, Jörg Kreuzer, MD, Sam Schulman, MD PhD, Ajay K Kakkar, MB, BS, PhD
Journal: Blood
Blood (2015) 126 (23): 4730.
https://doi.org/10.1182/blood.V126.23.4730.4730
Published: 2015
Journal Articles

Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up

Sam Schulman, MD, PhD, David Baanstra, MD, Henry Eriksson, MD, Samuel Z. Goldhaber, MD, Ajay Kakkar, MD, Clive Kearon, MD, PhD, Sebastian Schellong, MD, Jeffrey Friedman, MD
Journal: Blood
Blood (2012) 120 (21): 21.
https://doi.org/10.1182/blood.V120.21.21.21
Published: 2012
Journal Articles

The MAGELLAN Study: An Analysis of Outcomes Utilizing D-Dimer

Alexander T Cohen, Theodore E Spiro, Paul Burton, Harry R Büller, Lloyd Haskell, Da-Yi Hu, Russell D Hull, Alexandre Mebazaa, Geno J Merli, Sebastian Schellong, Alex C Spyropoulos, Victor F Tapson
Journal: Blood
Blood (2011) 118 (21): 542.
https://doi.org/10.1182/blood.V118.21.542.542
Published: 2011
Journal Articles

Rivaroxaban Compared with Enoxaparin for the Prevention of Venous Thromboembolism In Acutely Ill Medical Patients: MAGELLAN Study Methodology

Alexander Thomas Cohen, Theodore Erich Spiro, Harry Roger Büller, Lloyd Haskell, Da-Yi Hu, Russell Hull, Alexandre Mebazaa, Geno Merli, Sebastian Schellong, Alexander Spyropoulos, Victor Tapson
Journal: Blood
Blood (2010) 116 (21): 3331.
https://doi.org/10.1182/blood.V116.21.3331.3331
Published: 2010
Journal Articles

The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia

Norbert Lubenow, Peter Hinz, Simone Thomaschewski, Theresia Lietz, Michael Vogler, Andrea Ladwig, Michael Jünger, Matthias Nauck, Sebastian Schellong, Kathrin Wander, Georg Engel, Axel Ekkernkamp, Andreas Greinacher
Journal: Blood
Blood (2010) 115 (9): 1797–1803.
https://doi.org/10.1182/blood-2009-07-231506
Published: 2010
Journal Articles

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study

Clinical Trials & Observations
Harry R. Buller, Anthonie W. A. Lensing, Martin H. Prins, Giancarlo Agnelli, Alexander Cohen, Alexander S. Gallus, Frank Misselwitz, Gary Raskob, Sebastian Schellong, Annelise Segers
Journal: Blood
Blood (2008) 112 (6): 2242–2247.
https://doi.org/10.1182/blood-2008-05-160143
Published: 2008
Includes: Supplemental data
Journal Articles

Incidence and Disease Pattern of Venous Thrombembolism after Radical Prostatectomy.

Jan Beyer, MD, Sven Wessela, MD, Oliver Hakenberg, MD, Manfred Wirth, MD, Sebastian Schellong, MD
Journal: Blood
Blood (2005) 106 (11): 1627.
https://doi.org/10.1182/blood.V106.11.1627.1627
Published: 2005